PCR amplification of a triple-repeat genetic target directly from whole blood in 15 minutes as a proof-of-principle PCR study for direct sample analysis for a clinically relevant target

BMC Medical Genetics

Joel R TerMaat¹  Laura R Porter¹  Christopher M Connelly¹ 

[1] Streck, Inc., 7002 S. 109th Street, LaVista, Omaha 68128, NE, USA

关键词: Genetic screen;    Streck;    Philisa;    Triple-repeat;    Myotonic dystrophy;    Direct-Blood PCR;    Rapid-PCR;    Direct-PCR;   

Others  :  1090104
DOI  :  10.1186/s12881-014-0130-5

 received in 2013-10-17, accepted in 2014-11-24,  发布年份 2014

【 摘 要 】

Background

Most PCR-based diagnostics are still considered time- and labor-intensive due to disparate purification, amplification, and detection steps. Advancements in PCR enzymes and buffer chemistry have increased inhibitor tolerance, facilitating PCR directly from crude samples. Obviating the need for DNA purification, while lacking a concentration step, these direct sample methods are particularly apt for human genetic testing. However, direct PCR protocols have traditionally employed thermal cyclers with slow ramp rates and conservative hold times that significantly increase an assay’s time-to-result. For this proof-of-principle study, our objective was to significantly reduce sample preparation and assay time for a PCR-based genetic test, for myotonic dystrophy type 1 (DM1), by pairing an inhibitor-resistant enzyme mix with a rapid thermal cycler to analyze samples directly in whole blood.

Methods

DM1 genetic screening was done with an adapted conventional PCR approach that employed the Streck Philisa® Thermal Cycler, the inhibitor-resistant NEBNext® High-Fidelity 2X PCR Master Mix, and agarose gel electrophoresis or an Agilent 2100 Bioanalyzer for detection. The Gene Link™ Myotonic Dystrophy Genemer™ Kit was used as a reference assay kit to evaluate the rapid assay.

Results

In this work, a rapid and direct PCR assay testing 10% whole blood as template has been developed as an exclusionary screening assay for DM1, a triple-repeat genetic disorder. PCR amplification was completed in 15 minutes using 30 cycles, including in situ hot-start/cell lysis. Out of the 40 donors screened, this assay identified 23 (57.5%) as DM1 negative suggesting no need for further testing. These data are 100% concordant with data collected using the commercially available Gene Link Genemer™ Kit per the kit-specific PCR protocol.

Conclusions

The PCR assay described in this study amplified DM1 short tandem repeats in 15 minutes. By eliminating sample purification and slower conventional PCR protocols, we demonstrated how adaptation of current PCR technology and chemistries can produce a simple-to-use exclusionary screening assay that is independent of up-front sample prep, improving a clinical lab technician’s time-to-result. We envision this direct and rapid methodology could be applied to other conventional PCR-based genetic tests and sample matrices where genomic DNA is targeted for analysis within a given molecular diagnostic platform.

【 授权许可】

   
2014 Connelly et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Bussani C, Cioni R, Mattei A, Fambrini M, Marchionni M, Scarselli G: Prenatal diagnosis of common aneuploidies in transcervical samples using quantitative fluorescent-PCR analysis. Mol Diagn Ther 2007, 11(2):117-121.
• [2]Cursons RT, Jeyerajah E, Sleigh JW: The use of polymerase chain reaction to detect septicemia in critically ill patients. Crit Care Med 1999, 27(5):937-940.
• [3]Deng Z, Wu G, Li Q, Zhang X, Liang Y, Li D, Gao S, Lan Y: Noninvasive genotyping of 9 Y-chromosome specific STR loci using circulatory fetal DNA in maternal plasma by multiplex PCR. Prenat Diagn 2006, 26(4):362-368.
• [4]Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD, Wengenack NL, Rosenblatt JE, Cockerill FR 3rd, Smith TF: Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev 2006, 19(1):165-256.
• [5]Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ, Redman CW: Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999, 45(2):184-188.
• [6]Rautenberg P, Lubbert C, Weers W, Boetel E, Schweichler J, Zhou L, Costard-Jackle A, Kraemer-Hansen H, Harder TC: Evaluation of the AmpliSensor PCR and the SHARP signal detection system for the early prediction of symptomatic CMV infection in solid transplant recipients. J Clin Virol 1999, 13(1–2):81-94.
• [7]Robertson JM, Walsh-Weller J: An introduction to PCR primer design and optimization of amplification reactions. Methods Mol Biol 1998, 98:121-154.
• [8]Kranaster R, Marx A: Engineered DNA polymerases in biotechnology. Chembiochem 2010, 11(15):2077-2084.
• [9]Dauphin LA, Hutchins RJ, Bost LA, Bowen MD: Evaluation of automated and manual commercial DNA extraction methods for recovery of Brucella DNA from suspensions and spiked swabs. J Clin Microbiol 2009, 47(12):3920-3926.
• [10]Dauphin LA, Moser BD, Bowen MD: Evaluation of five commercial nucleic acid extraction kits for their ability to inactivate Bacillus anthracis spores and comparison of DNA yields from spores and spiked environmental samples. J Microbiol Methods 2009, 76(1):30-37.
• [11]Kramvis A, Bukofzer S, Kew MC: Comparison of hepatitis B virus DNA extractions from serum by the QIAamp blood kit, GeneReleaser, and the phenol-chloroform method. J Clin Microbiol 1996, 34(11):2731-2733.
• [12]Schuurman T, van Breda A, de Boer R, Kooistra-Smid M, Beld M, Savelkoul P, Boom R: Reduced PCR sensitivity due to impaired DNA recovery with the MagNA Pure LC total nucleic acid isolation kit. J Clin Microbiol 2005, 43(9):4616-4622.
• [13]Zhang Z, Kermekchiev MB, Barnes WM: Direct DNA amplification from crude clinical samples using a PCR enhancer cocktail and novel mutants of Taq. J Mol Diagn 2010, 12(2):152-161.
• [14]Kermekchiev MB, Kirilova LI, Vail EE, Barnes WM: Mutants of Taq DNA polymerase resistant to PCR inhibitors allow DNA amplification from whole blood and crude soil samples. Nucleic Acids Res 2009, 37(5):e40.
• [15]Schrader C, Schielke A, Ellerbroek L, Johne R: PCR inhibitors - occurrence, properties and removal. J Appl Microbiol 2012, 113(5):1014-1026.
• [16]Wang Y, Prosen DE, Mei L, Sullivan JCM, Vander Horn PB: A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro. Nucleic Acids Res 2004, 32(3):1197-1207.
• [17]Loh E, Choe J, Loeb LA: Highly tolerated amino acid substitutions increase the fidelity of Escherichia coli DNA polymerase I. J Biol Chem 2007, 282(16):12201-12209.
• [18]Aboud M, Oh HH, McCord B: Rapid direct PCR for forensic genotyping in under 25 min. Electrophoresis 2013, 34(11):1539-1547.
• [19]Kamsteeg EJ, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley MF, van Engelen BG, Schwartz M, Scheffer H: Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet 2012, 20(12):1203-1208.
• [20]Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, Hunter K, Stanton VP, Thirion JP, Hudson T: Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992, 69(2):385.
• [21]Prior TW: American College of Medical Genetics Laboratory Quality Assurance C: Technical standards and guidelines for myotonic dystrophy type 1 testing. Genet Med 2009, 11(7):552-555.